Camtobell (belotecan) / Chong Kun Dang - LARVOL DELTA

Sac-TMT in Pts With Previously Treated Advanced NSCLC With Actionable Genomic Alterations Other Than Classic EGFR Mutations (IASLC-WCLC 2026) - P2 | "Introduction : Sacituzumab tirumotecan (sac-TMT) is a TROP2 ADC developed with a unique bifunctional linker to conjugate a belotecan-derivative topoisomerase I inhibitor. Conclusions : Sac-TMT monotherapy demonstrated promising clinical activity with a manageable safety profile in previously treated advanced NSCLC pts with advanced NSCLC harboring AGAs other than classic EGFR mutations. These findings warrant further investigation of sac-TMT as a potential therapy for this population."

Clinical • Metastases • Dental Disorders • Hematological Disorders • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • Stomatitis • ALK • EGFR • KRAS • ROS1

Sacituzumab tirumotecan (Sac-TMT) plus pembrolizumab (Pembro) in participants (Pts) with advanced urothelial carcinoma (UC): Results from phase 2 2870-002/SKB264-II-06 study. (ASCO-GU 2026) - P2 | "Sac-TMT (MK-2870/SKB264) is a TROP2-directed ADC with a unique bifunctional linker that maximizes delivery of a novel belotecan-derived topo I inhibitor payload to tumor cells, that has shown promising antitumor activity in several tumor types, including as monotherapy in UC (Ye, D, et al...Pts with prior adjuvant or neoadjuvant platinum-based therapy or nivolumab were eligible if they had disease recurrence >12 mo after completing therapy... Sac-TMT + pembro showed promising antitumor activity at both 4 and 5 mg/kg in previously untreated, cisplatin-ineligible pts with la/mUC, with a manageable safety profile consistent with that of the individual treatment components. Further studies are warranted. NE, not estimable; NR, not reached."

Clinical • Metastases • P2 data • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer (ESMO 2024) - P2 | "Sac-TMT (also known as MK-2870/ SKB264) is a TROP2 ADC developed with novel linker to conjugate a belotecan-derivative topoisomerase I inhibitor...47.4% had received two prior lines of therapy, 52.6% had received bevacizumab, and 42.1% had received anti-PD-1 based therapy... Sac-TMT plus pembrolizumab demonstrated promising and durable antitumor activity with manageable safety profile. No new safety signal was observed. Considering the activity of this combination among pts who were pre-treated with anti-PD-1 based therapy, further investigation is warranted."

Clinical • Metastases • Cervical Cancer • Oncology • Solid Tumor

Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: results from the randomized, multi-center phase III OptiTROP-Lung04 study (ESMO 2025) - P3 | "Background Sac-TMT is a TROP2 ADC developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor. Sac-TMT demonstrated significant survival benefits over docetaxel in EGFRm NSCLC after failure of EGFR-TKI and platinum-based chemotherapy ( Fang et al., BMJ 2025 )...Methods Patients (pts) were randomized (1:1) to receive sac-TMT monotherapy (5 mg/kg Q2W) or chemotherapy (pemetrexed 500 mg/m 2 + carboplatin AUC 5 or cisplatin 75 mg/m 2 Q3W for 4 cycles followed by maintenance of pemetrexed)...*censored at the date of initiation of subsequent anti-tumor ADC drug therapy. Conclusions Sac-TMT is the first TROP2 ADC to significantly improve PFS and OS over platinum-based chemotherapy, with manageable safety in EGFR-TKI resistant NSCLC, positioning it as a potential new standard of care for this population."

Clinical • Late-breaking abstract • P3 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study (ESMO 2024) - P1/2 | "Sac-TMT (also known as MK-2870/SKB264) is a TROP2 ADC developed with a hydrolytically cleavable linker to conjugate a belotecan-derivative topoisomerase I inhibitor. Sac-TMT monotherapy has shown promising anti-tumor activity with a manageable safety profile in pts with heavily pre-treated advanced EC and OC."

Clinical • Metastases • P2 data • Endometrial Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • TACSTD2

Sacituzumab Tirumotecan in EGFR-Mutated NSCLC Patients With =3 Metastatic Sites: Subgroup Analysis of OptiTROP-Lung04 (IASLC-WCLC 2026) - P3 | "Introduction : Sacituzumab tirumotecan (sac-TMT) is a novel antibody-drug conjugate targeting trophoblast cell surface antigen 2 (Trop-2) with a unique bifunctional linker that maximizes delivery of a belotecan-derivative topo I inhibitor payload to tumor cells...Eligible pts with locally advanced or metastatic nonsquamous EGFRm NSCLC who progressed after EGFR-TKI therapy were randomized 1:1 to receive sac-TMT 5 mg/kg Q2W or pemetrexed plus platinum-based chemotherapy...Conclusions : In this subgroup analysis for patients with high tumor burden, sac-TMT provided substantial and clinical meaningful improvements in OS, PFS, and ORR compared with platinum-based chemotherapy. These result support sac-TMT as an effective treatment option following EGFR-TKI failure in patients with extensive metastatic disease."

Clinical • Metastases • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR

Updated ongoing phase I/II clinical trial results of AMT-116, a first-in-class anti-CD44v9 antibody-drug conjugate (ADC), in patients with advanced solid tumors (ESMO 2025) - P1, P1/2 | "AMT-116 is a first-in-class antibody-drug conjugate (ADC) comprising a humanized anti-CD44v9 IgG1 antibody conjugated to KL610023, a novel belotecan-derived topoisomerase I inhibitor, via a cleavable hydrolysable linker (average drug-to-antibody ratio: 7–8). Conclusions AMT-116 demonstrated a manageable safety profile and promising antitumor activity across solid tumors especially in EGFR wild-type NSCLC. Enrollments are ongoing to further assess efficacy in NSCLC and other potential cancer types."

Clinical • Metastases • P1/2 data • Anal Carcinoma • Head and Neck Cancer • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • EGFR

Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study. (ASCO 2024) - P2, P3 | "Background: Sacituzumab Tirumotecan (SKB264/MK-2870)is a TROP2 ADC developed with novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor. SKB264 in combination with KL-A167 demonstrated promising efficacy results in treatment naive advanced NSCLC with manageable safety profile. SKB264 Q2W was recommended for further investigation. A Phase 3 study of SKB264 Q2W plus pembrolizumab vs pembrolizumab in 1L metastatic NSCLC with PD-L1 TPS ≥ 50% (NCT06170788) is ongoing."

Clinical • Combination therapy • IO biomarker • Metastases • P2 data • Anemia • Hematological Disorders • Immunology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study. (ASCO 2024) - P3 | "Sacituzumab tirumotecan (SKB264/MK-2870) is a TROP2 ADC developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4... In this randomized phase Ⅲ trial, SKB264 was compared with physician's choice of chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine) in pts with locally recurrent or metastatic TNBC who had received two or more prior therapies including at least one for metastatic setting... Sacituzumab tirumotecan monotherapy demonstrated statistically significant and clinically meaningful PFS and OS benefit over chemotherapy, with a manageable safety profile in pts with heavily pretreated advanced TNBC and limited treatment options."

Clinical • IO biomarker • Metastases • P3 data • Anemia • Breast Cancer • Hematological Disorders • Oncology • Solid Tumor • Triple Negative Breast Cancer • TACSTD2

Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study. (ASCO 2025) - P2, P3 | "Sac-TMT (MK-2870/SKB264) is a TROP2 ADC developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor. Sac-TMT demonstrated promising anti-tumor activity with a manageable safety profile as a first-line treatment for pts with a/mTNBC, independent of the PD-L1 status. A Phase 3 study comparing sac-TMT vs investigator's choice of chemotherapy in first-line PD-L1-negative (CPS < 10) a/mTNBC is currently underway (NCT06279364)."

Clinical • Metastases • P2 data • Anemia • Breast Cancer • Dental Disorders • Fatigue • Interstitial Lung Disease • Oncology • Pain • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Stomatitis • Triple Negative Breast Cancer

Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT05631262 Background: Sac-TMT (MK-2870/SKB264), a novel TROP2 ADC developed to conjugate a belotecan-derivative topoisomerase I inhibitor, has shown encouraging antitumor activity in EGFRm NSCLC pts in phase Ⅰ trial (Fang et al. Sac-TMT demonstrated improved ORR, PFS and OS compared to docetaxel, with manageable safety profile in pts with previously treated advanced EGFRm NSCLC. These results highlight significant survival benefits and suggest that sac-TMT could emerge as a new standard of care for this population."

Clinical • Metastases • Anemia • Dental Disorders • Febrile Neutropenia • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Stomatitis • EGFR

Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors. (ASCO 2024) - P1 | "AMT-116 is a first-in-class antibody-drug conjugate (ADC) targeting CD44v9, by conjugating a novel topoisomerase I inhibitor, belotecan derivative named KL610023 (Sichuan Kelun-Biotech) to a humanized anti-CD44v9 immunoglobulin G1 (IgG1) antibody via a hydrolysable linker with an average drug-to-antibody ratio of 7-8. These preliminary data indicate that AMT-116 is well tolerated at the first two dose levels in patients with heavily pretreated advanced solid tumors. Dose escalation is ongoing. Clinical trial information: NCT05725291."

Clinical • Metastases • P1 data • Anal Carcinoma • Cervical Cancer • Fatigue • Gastric Cancer • Gastrointestinal Cancer • Hematological Disorders • Hepatocellular Cancer • Leukopenia • Oncology • Solid Tumor • Squamous Cell Carcinoma

SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): Results from a phase I/II, single-arm, basket trial (ESMO 2023) - P1/2 | "SKB264 is a novel anti-TROP2 ADC developed using sulfonyl pyrimidine-CL2A-carbonate linker to conjugate its payload, a belotecan-derivative topoisomerase I inhibitor, to achieve an average Drug-to-antibody Ratio (DAR) of 7.4. Conclusions SKB264 at 5 mg/kg demonstrates a manageable safety profile and promising antitumor activity in pts with pre-treated HR+/HER2- mBC. Two phase 3 studies are currently planned in HR+/HER2- mBC, one in China for pts after at least one chemo for mBC and a second global for pts previously untreated with chemo for mBC, both comparing SKB264 vs investigator selected chemo."

Metastases • P1/2 data • Pan tumor • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • TACSTD2

TroFuse-032: A phase 3, randomized study of pembrolizumab (Pembro) + sacituzumab tirumotecan (Sac-TMT) or chemotherapy (Chemo) followed by pembro + chemo for early-stage triple-negative breast cancer (TNBC) or HR-low+/HER2− breast cancer (ESMO 2025) - P3 | "Sac-TMT (also known as MK-2870/SKB264), a novel antibody-drug conjugate composed of an anti-TROP2 antibody coupled to a cytotoxic belotecan derivative via a novel linker, has demonstrated significant PFS and OS benefits vs chemo in patients with metastatic TNBC. Enrollment is ongoing. Table: 420TiP Study Treatment Neoadjuvant Adjuvant Cycles a 1–2 Cycles a 3–4 Cycles a 5–9 Arm 1 Pembro b + sac-TMT (4 mg/kg Q2W) Pembro b + paclitaxel c + carboplatin d Pts with pCR: Pembro (400 mg Q6W or 200 mg Arm 2 Pembro b + paclitaxel c + carboplatin d Pembro b + doxorubicin e or epirubicin f + cyclophosphamide g Q3W) Pts with residual disease: Pembro (400 mg Q6W or 200 mg Q3W) + optional treatment of physician's choice (olaparib h , capecitabine i or doxorubicin j,k or epirubicin l,k + cyclophosphamide m,k ) a Cycle length = 6 wks; b 200 mg Q3W; c 80 mg/m2QW; d AUC 1.5 QW; e 60 mg/m2Q3W; f 90 mg/m2Q3W; g 600 mg/m2Q3W; h 100 or 150 mg every 2 wks; i 1000 to 1250 mg/m2every 2..."

Clinical • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • TACSTD2

Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study. (ASCO 2025) - P2, P3 | "Clinical Trial Registration Number: NCT05351788 Background: Sac-TMT (MK-2870/SKB264) is a TROP2 ADC developed with a novel linker to conjugate a belotecan-derivative topoisomerase I inhibitor. Sac-TMT in combination with tagitanlimab demonstrated promising antitumor activity in treatment-naive advanced non-squamous NSCLC. The durable clinical activities were observed regardless of PD-L1 expression. This combination therapy showed a tolerable safety profile based on known profiles of the individual agents, with no new safety signals observed."

Clinical • Combination therapy • IO biomarker • Metastases • P2 data • Anemia • Dental Disorders • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Stomatitis

SACITUZUMAB TIRUMOTECAN MONOTHERAPY IN POST-PLATINUM ADVANCED OR METASTATIC ENDOMETRIAL CARCINOMA: RESULTS FROM A PHASE 1/2 STUDY (2870-001/KL264-01) (IGCS 2026) - P1/2, P3 | "Introduction: Sacituzumab tirumotecan (sac-TMT) is a TROP2-directed ADC with a unique, bifunctional linker that maximizes delivery of a belotecan-derived topoisomerase I payload to tumor cells. As of November 30, 2025, of 158 participants who had received sac-TMT, 101 (63.9%) had received ≥2 prior lines of therapy. The median (range) follow-up was 18.1 (14.2–22.2) months in the 4-mg/kg group (n=114) and 28.1 (25.5–34.4) months in the 5-mg/kg group (n=44). In the 4- and 5-mg/kg groups, respectively, 24 (21.1%) and 2 (4.5%) participants remained on treatment at data cutoff; 67 (58.8%) and 33 (75.0%) discontinued due to PD."

Metastases • Monotherapy • P1/2 data • Endometrial Cancer • Oncology • Solid Tumor • TOP1

Sacituzumab tirumotecan (sac-TMT) vs investigator's choice of chemotherapy (ICC) in previously treated locally advanced or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Results from the randomized, multi-center phase III OptiTROP-Breast02 study (ESMO 2025) - P3 | "Background Sac-TMT is a TROP2 ADC developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor...Methods Pts with HR+/HER2- BC who had progression on CDK4/6 inhibitors and received at least one prior line of chemotherapy in the advanced/metastatic setting were randomized (1:1) to receive sac-TMT 5 mg/kg Q2W or ICC (eribulin, vinorelbine, capecitabine, or gemcitabine)...Grade ≥ 3 TRAEs occurred in 62.0% and 64.8% of pts in sac-TMT and ICC with the most common being neutrophil count decreased (44.5% vs 51.5%) and WBC decreased (31.0% vs 31.6%); TRAE led to discontinuation in 0% and 0.5% of pts; pneumonitis occurred in 1.5% and 1.0% of pts (all grade 1-2) in sac-TMT and ICC, respectively. Conclusions Sac-TMT demonstrated significantly improved PFS compared to ICC, with manageable safety profile in pts with previously treated HR+/HER2- BC including both HER2-zero and HER2-low, positioning it as a new therapeutic option for..."

Clinical • Late-breaking abstract • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

TroFuse-015: A phase III study of trophoblast antigen 2 (TROP2)–directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA) (ESMO Asia 2024) - P1/2, P3 | "Sac-TMT (also known as MK-2870/SKB264) is a TROP2-directed antibody-drug conjugate developed with a novel linker to a belotecan-derivative topoisomerase I inhibitor...Approximately 450 patients will be randomly assigned (1:1) to receive sac-TMT 4 mg/kg IV on days 1, 15, and 29 of every 42-day cycle or TPC (TAS-102 [35 mg/m 2 by mouth (PO) twice daily (BID) on days 1-5 and 8-12 of every 28-day cycle]; irinotecan [150 mg/m 2 IV on days 1 and 15 of every 28-day cycle]; paclitaxel [80 mg/m 2 IV on days 1, 8, and 15 of every 28-day cycle]; or docetaxel [75 mg/m 2 IV on day 1 of every 21-day cycle])...Secondary end points are PFS, ORR, and DOR (all per RECIST v1.1 by BICR), safety, and tolerability. Enrollment is currently ongoing."

Metastases • P3 data • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • TACSTD2

Intravesical sacituzumab tirumotecan in participants with intermediate-risk non–muscle-invasive bladder cancer: The phase 1/2 TroFuse-027 study. (ASCO 2025) - P1/2 | "Sacituzumab tirumotecan (sac-TMT; MK-2870) is an antibody-drug conjugate consisting of a humanized anti-TROP2 monoclonal antibody, a linker, and a cytotoxic belotecan-derivative topoisomerase I inhibitor...Secondary objectives are pharmacokinetics and complete response rate (the proportion of participants with the absence of visible tumors at the 12-week assessment after initiating treatment) and duration of complete response per local assessment. Future studies (phase 2) will be initiated on completion of dose escalation and based on the totality of data."

P1/2 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

A phase I/II evaluation of sacituzumab tirumotecan plus pembrolizumab with chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): Arm 5 of KEYMAKER-U06 substudy 06E (ESMO-GI 2026) - P1/2 | "Background Sacituzumab tirumotecan (sac-TMT) is a TROP2-directed antibody-drug conjugate comprising a humanized TROP2 monoclonal antibody, a linker, and topoisomerase I inhibitor (belotecan derivative)...Other study arms were previously described in trial-in-progress presentations; briefly, these include arm 1 (control; pembro + chemo [mFOLFOX6]); arm 2 (ifinatamab deruxtecan [I-DXd] + pembro); arm 3 (I-DXd + pembro + 5-fluorouracil [5-FU] + leucovorin/levoleucovorin); and arm 4 (I-DXd + pembro + 5-FU + leucovorin/levoleucovorin + oxaliplatin).Trial design Eligible participants (pts) are aged ≥18 years with untreated, locally advanced, unresectable or metastatic ESCC; measurable disease per RECIST v1.1 by investigator review (verified by BICR); and an ECOG PS score of 0 or 1...Other objectives include DOR and PFS per RECIST v1.1 by BICR, OS, and pharmacokinetics of sac-TMT. Enrollment is ongoing."

Metastases • P1/2 data • Esophageal Squamous Cell Carcinoma • Gastroesophageal Cancer • Gastrointestinal Cancer • Oncology

TroFuse-022/ENGOT-ov84/GOG-3103 part 2: A phase 3 study of maintenance therapy with sacituzumab tirumotecan ± bevacizumab vs standard of care following second-line platinum-based doublet chemotherapy for platinum-sensitive recurrent ovarian cancer. (ASCO 2026) - P3 | "Sacituzumab tirumotecan (sac-TMT) is a TROP2-directed antibody-drug conjugate with a unique, bifunctional linker that maximizes delivery of a belotecan-derived topoisomerase 1 inhibitor payload to tumor cells...All pts must have received 6 cycles of 2L carboplatin-based doublet chemo ± bev and achieved NED, CR, PR, or SD per investigator assessment; pts with SD must have received bev in combination with 2L chemo and be eligible to continue treatment with bev...PFS and OS will be assessed in pts with medium/high TROP2 expression tumors and all pts. The study is ongoing, and enrollment in part 2 is open."

Clinical • P3 data • Platinum sensitive • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • BRCA • HRD • TACSTD2

TROFUSE-011: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF SACITUZUMAB TIRUMOTECAN ± PEMBROLIZUMAB VS TREATMENT OF PHYSICIAN’S CHOICE FOR PREVIOUSLY UNTREATED LOCALLY RECURRENT UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER WITH PD-L1 CPS <10 (BMC-BBCS 2026) - P3 | "Sacituzumab tirumotecan (sac-TMT) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) with a unique, bifunctional linker that maximizes delivery of a belotecan-derived topoisomerase I inhibitor payload to tumor cells...TPC consists of one of: paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin... Not applicable."

Clinical • IO biomarker • Metastases • P3 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PD-L1

Legumain-responsive albumin-binding prodrug enables tumor-selective drug release and immunomodulatory remodeling for enhanced antitumor efficacy in ovarian cancer. (PubMed, Int J Pharm) - "WC10-003 exhibits favorable pharmacological properties, including albumin-mediated stabilization and legumain-dependent tumor activation, resulting in enhanced antitumor efficacy in preclinical ovarian cancer models. These findings highlight a pharmacologically driven prodrug strategy for improving cytotoxic drug performance and support its further evaluation in combination with immunotherapy."

Journal • Oncology • Ovarian Cancer • Solid Tumor • LGMN

TREATMENT PATTERNS AND HEALTHCARE COSTS IN PATIENTS WITH SMALL-CELL LUNG CANCER IN SOUTH KOREA: A NATIONWIDE REAL-WORLD STUDY (ISPOR 2026) - "Second-line therapies included etoposide/platinum, irinotecan/platinum, and belotecan, with differences in relative utilization between ES and LS patients. This nationwide real-world study provides stage-specific real-world evidence on systemic therapy utilization and healthcare costs across lines of therapy in SCLC."

Clinical • HEOR • Real-world • Real-world evidence • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Trofuse-023: A phase 3, randomized, open-label study of pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT) as first-line treatment for metastatic squamous non-small-cell lung cancer (NSCLC) (AACR 2025) - "Sac-TMT (also known as MK-2870/SKB264) is an antibody-drug conjugate composed of an anti-TROP2 antibody coupled to a belotecan-derivative topoisomerase I inhibitor KL610023 (drug-to-antibody ratio, 7.4) via a novel linker...Patients will receive induction of pembrolizumab (200 mg IV Q3W) plus chemotherapy (carboplatin AUC 6 mg/mL/min IV Q3W and paclitaxel 200 mg/m2 IV Q3W or nab-paclitaxel 100 mg/m2 IV weekly) for 4 cycles...Other secondary endpoints include safety and patient-reported outcomes. Enrollment began on June 10, 2024, and the study is ongoing globally with 210 planned sites."

Clinical • IO biomarker • Metastases • P3 data • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • TACSTD2